Krystal Biotech Receives 'Moderate Buy' Rating from Analysts

Biotechnology company's stock gets consensus recommendation from research analysts

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Krystal Biotech, Inc. (NASDAQ:KRYS), a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases, has received a consensus 'Moderate Buy' rating from the ten analysts currently covering the company, according to a MarketBeat Ratings report. One analyst has rated the stock as a 'hold', while nine have issued 'buy' recommendations.

Why it matters

Krystal Biotech's lead product candidate, KB103, is designed to treat dystrophic epidermolysis bullosa (DEB), a severe and debilitating blistering condition. The 'Moderate Buy' rating from analysts suggests they believe the company's gene therapy approach has significant potential, which could be important for attracting investor interest and funding to advance its pipeline.

The details

The average 12-month price target among the analysts covering Krystal Biotech is $326.25. Several research firms have recently weighed in on the stock, with Jefferies Financial Group, Chardan Capital, TD Cowen, and Bank of America all raising their price targets and maintaining 'buy' ratings.

  • Krystal Biotech reported its latest quarterly results on February 17, 2026.

The players

Krystal Biotech, Inc.

A clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. The company's lead product candidate is KB103, designed to treat dystrophic epidermolysis bullosa (DEB).

Dino A. Rossi

A director at Krystal Biotech who sold 18,950 shares of the company's stock on February 19, 2026.

Kathryn Romano

The chief accounting officer at Krystal Biotech who sold 12,500 shares of the company's stock on February 9, 2026.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.